Kymera Therapeutics (KYMR) Receivables (2020 - 2025)

Kymera Therapeutics (KYMR) has 6 years of Receivables data on file, last reported at $40.0 million in Q2 2025.

• Receivables for Q2 2025 came in at $40.0 million, up 2252.94% year-over-year; the trailing twelve-month figure through Jun 2025 was $40.0 million (up 2252.94% YoY), and the FY2024 annual result was $900000.0, down 95.2% from the prior year.
• Receivables rose to $40.0 million in Q2 2025 per KYMR's latest filing, from $900000.0 in the prior quarter.
• Over five years, Receivables peaked at $40.0 million in Q2 2025 and troughed at $900000.0 in Q1 2021.
• A 5-year average of $8.5 million and a median of $1.9 million in 2024 frame the typical range for Receivables.
• The sharpest annual moves came in 2024 and 2025: Receivables sank 95.2% in 2024, then surged 2252.94% in 2025.
• A 5-year view of Receivables shows it stood at $900000.0 in 2021, then soared by 177.78% to $2.5 million in 2022, then jumped by 650.48% to $18.8 million in 2023, then slumped by 95.2% to $900000.0 in 2024, then jumped by 4344.44% to $40.0 million in 2025.
• Business Quant data shows KYMR's Receivables at $40.0 million in Q2 2025, $900000.0 in Q4 2024, and $1.3 million in Q3 2024.